Consolidated Statements of Changes in Shareholders' Equity - USD ($) $ in Thousands	Total		Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Unearned Employee Stock Ownership Plan Shares	Retained Earnings	Retained Earnings Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Income (Loss ), net
Balance at beginning of period at Dec. 31, 2018	$ 117,476			$ 66,008	$ 36,972	$ (1,734)	$ 17,557		$ (1,327)
Balance at beginning of period, Shares at Dec. 31, 2018				13,201,682
Net income (loss)	5,056						5,056
Other comprehensive income, net	1,667								1,667
Stock options exercised, net	9			$ 26	(17)
Stock options exercised, Shares				5,173
Director and executive stock grant	148			$ 92	56
Director and executive stock grant, Shares				18,396
Restricted stock awards				$ 545	(545)
Restricted stock awards,shares				109,051
ESOP collateral release	141					141
Share-based compensation expense	315				315
Balance at end of period at Sep. 30, 2019	124,857		$ 45	$ 66,671	36,781	(1,593)	22,658	$ 45	340
Balance at end of period, Shares at Sep. 30, 2019				13,334,302
Balance at beginning of period at Jun. 30, 2019	122,617			$ 66,662	36,699	(1,668)	20,817		107
Balance at beginning of period, Shares at Jun. 30, 2019				13,332,484
Net income (loss)	1,841						1,841
Other comprehensive income, net	233								233
Restricted stock awards				$ 9	(9)
Restricted stock awards,shares				1,818
ESOP collateral release	75					75
Share-based compensation expense	91				91
Balance at end of period at Sep. 30, 2019	124,857		$ 45	$ 66,671	36,781	(1,593)	22,658	$ 45	340
Balance at end of period, Shares at Sep. 30, 2019				13,334,302
Balance at beginning of period at Dec. 31, 2019	$ 126,185	[1]		$ 66,309	36,658	(1,525)	24,660		83
Balance at beginning of period, Shares at Dec. 31, 2019	13,261,801	[1]		13,261,801
Net income (loss)	$ (6,648)						(6,648)
Other comprehensive income, net	1,133								1,133
Stock options exercised, net	88			$ 83	5
Stock options exercised, Shares				16,689
Director and executive stock grant	164			$ 109	55
Director and executive stock grant, Shares				21,789
Restricted stock awards				$ 226	(226)
Restricted stock awards,shares				45,105
Shares repurchased pursuant to ESOP	(25)			$ (16)	(9)
Shares repurchased pursuant to ESOP,shares				(3,280)
ESOP collateral release	199					199
Share-based compensation expense	333				333
Balance at end of period at Sep. 30, 2020	$ 121,429			$ 66,711	36,816	(1,326)	18,012		1,216
Balance at end of period, Shares at Sep. 30, 2020	13,342,104			13,342,104
Balance at beginning of period at Jun. 30, 2020	$ 119,690			$ 66,670	36,729	(1,394)	16,519		1,166
Balance at beginning of period, Shares at Jun. 30, 2020				13,334,049
Net income (loss)	1,493						1,493
Other comprehensive income, net	50								50
Director and executive stock grant	60			$ 51	9
Director and executive stock grant, Shares				10,055
Restricted stock forfeitures				$ (10)	10
Restricted stock forfeitures, shares				(2,000)
ESOP collateral release	68					68
Share-based compensation expense	68				68
Balance at end of period at Sep. 30, 2020	$ 121,429			$ 66,711	$ 36,816	$ (1,326)	$ 18,012		$ 1,216
Balance at end of period, Shares at Sep. 30, 2020	13,342,104			13,342,104

[1] Derived from audited December 31, 2019 Consolidated Financial Statements.